News summary
[Hengrui Medicinebeamdrivecrashdeathstairc: Fluzopari capsules have been approved for listing for new indications] Securities Times e Company News, Hengrui Pharmaceutical (600276) announced on the evening of May 21 that the company has received approval from the State Food and Drug Administration for the issuance of Fluzopari capsules "Drug Registration Certificate", approving the company's Class 1 new drug, PARP inhibitor,beamdrivecrashdeathstairc...
Newsletter text
[Hengrui Pharmaceutical: Fluzopali Capsules have been approved for new indications] Securities Times e Company News, Hengrui Pharmaceutical (600276) announced on the evening of May 21 that the company received approval from the State Food and Drug Administration for the issuance of Fluzopali Capsules. The "Drug Registration Certificate" approved the launch of a new class 1 new drug developed by the company, the PARP inhibitor Fluzopali Capsules for new indications. This is the third indication for which Fluzopali has been approved for marketing.